{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:05:54Z","timestamp":1763017554722,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.bbmt.2015.07.012","type":"journal-article","created":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T22:05:27Z","timestamp":1436825127000},"page":"2115-2122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors"],"prefix":"10.1016","volume":"21","author":[{"given":"Jennifer A.","family":"Kanakry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Gocke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lode J.","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda L.","family":"Blackford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ephraim J.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol Ann","family":"Huff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Borrello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary L.","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish","family":"Shanbhag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Luznik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvette L.","family":"Kasamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.07.012_bib1","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2010-05-283051","article-title":"Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia","volume":"116","author":"Cooley","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.012_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib4","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.012_bib5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 2","key":"10.1016\/j.bbmt.2015.07.012_bib6","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.4081\/pr.2011.s2.e15","article-title":"Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide","volume":"3","author":"Munchel","year":"2011","journal-title":"Pediatr Rep"},{"key":"10.1016\/j.bbmt.2015.07.012_bib7","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.012_bib8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbmt.2014.02.001","article-title":"Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide","volume":"20","author":"Castagna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.012_bib9","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","article-title":"Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation","volume":"18","author":"Ciurea","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.012_bib10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","article-title":"Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose post-transplantation cyclophosphamide: effect of HLA disparity on outcome","volume":"16","author":"Kasamon","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.012_bib11","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib12","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/0008-5472.CAN-07-6523","article-title":"Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype","volume":"68","author":"Congy-Jolivet","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2015.07.012_bib13","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship","volume":"64","author":"Dall'Ozzo","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2015.07.012_bib14","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2011-05-351411","article-title":"Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism","volume":"118","author":"Veeramani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib15","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.012_bib16","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib17","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2006-01-009480","article-title":"FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma","volume":"108","author":"Kim","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.2005.06.059","article-title":"Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia","volume":"23","author":"Treon","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.012_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.012_bib20","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib21","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.012_bib22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2015.07.012_bib23","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.012_bib24","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib25","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.012_bib26","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","article-title":"Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature","volume":"89","author":"Wolach","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bbmt.2015.07.012_bib28","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03, Available at: http:\/\/ctep.cancer.gov\/default.htm\u00a02010."},{"key":"10.1016\/j.bbmt.2015.07.012_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric-estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2015.07.012_bib30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2015.07.012_bib31","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.bbmt.2015.07.012_bib32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.bbmt.2013.11.029","article-title":"A\u00a0phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients","volume":"20","author":"Sauter","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.012_bib33","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.682.682","volume":"124","author":"Laport","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/JCO.2009.25.0274","article-title":"Immunoglobulin G Fc receptor FcgammaRIIIa 158 V\/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma","volume":"28","author":"Weng","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.012_bib35","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1182\/blood-2011-12-395970","article-title":"Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence","volume":"119","author":"Arai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib36","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2013-04-495895","article-title":"Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial","volume":"122","author":"Cutler","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","article-title":"Rituximab for steroid-refractory chronic graft-versus-host disease","volume":"108","author":"Cutler","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib38","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood-2014-04-571125","article-title":"Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD","volume":"124","author":"Khoder","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.012_bib39","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2009.04.003","article-title":"Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis","volume":"15","author":"Kharfan-Dabaja","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.012_bib40","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/bmt.2008.12","article-title":"Rituximab as salvage therapy for refractory chronic GVHD","volume":"41","author":"Mohty","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.012_bib41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/sj.leu.2403996","article-title":"Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease","volume":"20","author":"Okamoto","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.07.012_bib42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.bmt.1705725","article-title":"Treatment of refractory chronic GVHD with rituximab: a GITMO study","volume":"40","author":"Zaja","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.012_bib43","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1365-2141.2009.07674.x","article-title":"Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation","volume":"145","author":"Ratanatharathorn","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.07.012_bib44","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2009-10-248609","article-title":"Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response","volume":"116","author":"Abes","year":"2010","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115004681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115004681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:53:31Z","timestamp":1761058411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115004681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1083879115004681"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.012","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}